Poxel/Sumitomo's Novel Diabetes Therapy Imeglimin Nears Japan Market
A Phase III-Ready Partnering Opportunity For EU/US
Poxel’s potential first-in-class diabetes therapy, imeglimin, could be approved in Japan this year, and a new partner is being sought for the EU and US – events that would transform the outlook for the decade-old Merck Serono spin-out.
